Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SARS hyperimmune globulin
- Development stage
- Unknown
- Lead developer
- Grifols
- Modality
- Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SARS hyperimmune globulin is a plasma-derived polyclonal antibody therapy developed by Weiguang Biological Products for the treatment of Severe Acute Respiratory Syndrome (SARS). It is produced by purifying the immunoglobulin fraction from the convalescent plasma of donors who have recovered from SARS-CoV-1 infection. The product contains high titers of neutralizing antibodies that specifically target the SARS coronavirus. Upon intravenous administration, these antibodies provide immediate passive immunity by binding to viral antigens, thereby neutralizing the virus and preventing the infection of host cells. This therapeutic approach is intended to reduce viral load and improve clinical outcomes in patients with acute coronavirus infection.
- Other names
- SARS-specific human immunoglobulinAnti-SARS-CoV-1 immunoglobulinAnti-SARS-CoV1 immunoglobulinAnti-SARS-CoV 1 immunoglobulinSARS-IVIGSARS-specific human immunoglobulin for intravenous injection
02
Targets
N (Nucleocapsid protein)Omicron RBD (SARS-CoV-2 Omicron spike receptor-binding domain)S1-NTD (SARS-CoV-2 spike S1 N-terminal domain)
Beyond the preview
Go deeper on SARS hyperimmune globulin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SARS hyperimmune globulin.